

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ALPHATEC HOLDINGS, INC., and ALPHATEC SPINE, INC.,  
Petitioner,

v.

NUVASIVE, INC.,  
Patent Owner.

---

IPR2019-00361  
Patent 8,187,334 B2

---

Before DENISE M. POTHIER, HYUN J. JUNG, and  
SHEILA F. McSHANE, *Administrative Patent Judges*.

JUNG, *Administrative Patent Judge*.

JUDGMENT

Final Written Decision

Determining Some Challenged Claims Unpatentable

Denying Patent Owner's Motion to Exclude

35 U.S.C. § 318(a)

## I. INTRODUCTION

We have jurisdiction under 35 U.S.C. § 6. This Final Written Decision is issued pursuant to 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73.

### A. *Background and Summary*

Alphatec Holdings, Inc., and Alphatec Spine, Inc., (collectively, “Petitioner”) filed a Petition (Paper 2, “Pet.”) requesting institution of an *inter partes* review of claims 6–9 and 18 of U.S. Patent No. 8,187,334 B2 (Ex. 1001, “the ’334 patent”). NuVasive Inc. (“Patent Owner”) filed a Preliminary Response (Paper 12). Pursuant to 35 U.S.C. § 314, we instituted an *inter partes* review of the ’334 patent. Paper 19 (“Dec. to Inst.”). In particular, we instituted review of claims 6–9 and 18 on all presented challenges. Dec. to Inst. 2, 24, 25, 26, 29, 30, 38, 41, 43.

After institution, Patent Owner filed a Response (Paper 28, “PO Resp.”), to which Petitioner filed a Reply (Paper 35, “Pet. Reply”). Patent Owner thereafter filed a Sur-Reply (Paper 41, “PO Sur-reply”). Patent Owner also filed a Motion to Exclude (Paper 39, “Mot.”), and Petitioner filed an Opposition to Patent Owner’s Motion to Exclude (Paper 45, “Opp.”), to which Patent Owner filed a Reply (Paper 49, “Mot. Reply”). In an Order (Paper 38), we authorized Patent Owner to file a Supplemental Sur-reply, which was filed (Paper 42) and Petitioner to file a Supplemental Sur-sur-reply, which was also filed (Paper 43). An oral hearing in this proceeding was held on April 3, 2020; a transcript of the hearing is included in the record (Paper 56, “Tr.”). *See also* Exs. 1066, 2062 (parties’ transcript errata sheets).

For the reasons that follow, we determine that Petitioner has shown by a preponderance of the evidence that claims 6–9, but not claim 18, of the

IPR2019-00361  
Patent 8,187,334 B2

'334 patent are unpatentable. We also deny Patent Owner's Motion to Exclude.

*B. Real Parties in Interest*

Petitioner states that "Alphatec Holdings, Inc. and Alphatec Spine, Inc. are the real-parties-in-interest for purposes of this proceeding." Pet. 75. "In accordance with 37 C.F.R. § 42.8(b)(1), Patent Owner identifies NuVasive, Inc. as the real party-in-interest." Paper 4, 2.

*C. Related Matters*

The parties indicate that the '334 patent has been asserted in *NuVasive, Inc. v. Alphatec Holdings, Inc.*, Case No. 3:18-cv-00347-CAB-MDD (S.D. Cal.) and *Warsaw Orthopedic, Inc. v. NuVasive, Inc.*, Case No. 3:12-cv-002738-CAB-MDD (S.D. Cal.). Pet. 75; Paper 4, 2. The parties also indicate that the '334 patent is the subject of IPR2019-00546. Paper 4, 2; Paper 6, 2.


Patent Owner additionally notes that the '334 patent was previously challenged in IPR2013-00507 and IPR2013-00508. Paper 4, 2 (citing *In re NuVasive, Inc.*, 841 F.3d 966 (Fed. Cir. 2016)); *see also* Pet. 1 (stating that "the Federal Circuit affirmed the Board's finding in IPR2013-00507 (Ex. 1004) that sole independent claim 1 of the '334 patent and eighteen dependent claims (2–5, 10, 11, 14, 15, and 19–28) are invalid"). A related patent, U.S. Patent No. 8,361,156 B2, is challenged in IPR2019-00362. Pet. 75; Paper 4, 2; Paper 6, 2.

*D. The '334 Patent (Ex. 1001)*

The '334 patent issued May 29, 2012, from an application filed April 4, 2011, which is a continuation of an application filed on March 29, 2005, and claims priority to a provisional application filed on March 29, 2004. Ex. 1001, codes (22), (45), (60), (63), 1:7–13.

The '334 patent particularly relates to “a system and method for spinal fusion comprising a spinal fusion implant of non-bone construction . . . to introduce the spinal fusion implant into any of a variety of spinal target sites.” *Id.* at 1:18–21.

Figure 2 of the '334 patent is reproduced below.



**FIG. 2**

Figure 2 shows a perspective view of a lumbar fusion implant. *Id.* at 3:36. The spinal fusion implant is introduced into the disc space via a lateral approach to the spine or via a posterior, anterior, antero-lateral, or postero-lateral approach, and is made from a radiolucent material, such as PEEK (poly-ether-ether-ketone). *Id.* at 5:10–15, 5:29–33.

Common attributes of the various embodiments of spinal fusion implant 10 includes top surface 31, bottom surface 33, lateral sides 14, proximal side 22, and distal side 16. *Id.* at 6:6–9, Figs. 2–3. Spinal fusion

implant 10 may have “a width ranging between 9 and 18 mm, a height ranging between 8 and 16 mm, and a length ranging between 25 and 45 mm.” *Id.* at 5:15–19.

Spinal fusion implant 10 also preferably includes anti-migration features, such as ridges 6 and pairs of spike elements 7–9, designed to increase friction between spinal fusion implant 10 and adjacent contacting surfaces of vertebral bodies. *Id.* at 6:21–32, Figs. 2–3. Spike elements 7–9 are preferably made from materials having radiopaque characteristics. *Id.* at 6:35–38.

Spinal fusion implant 10 has fusion apertures 2, separated by medial support 50, extending through top surface 31 and bottom surface 33. *Id.* at 6:57–59, Figs. 2–3. “[F]usion apertures 2 function primarily as an avenue for bony fusion between adjacent vertebrae.” *Id.* at 6:59–61.

#### *E. Illustrative Claims*

The '334 patent has 28 claims. In IPR2013-00507, claim 18 was found to be “patentable,” and claims 1–5, 10, 11, 14, 15, and 19–28 were cancelled. Ex. 1001, 34. Petitioner challenges claims 6–9 and 18, all of which ultimately depend from cancelled claim 1. Claims 1, 6, and 18 are reproduced below.

1. A spinal fusion implant of non-bone construction positionable within an interbody space between a first vertebra and a second vertebra, said implant comprising:

an upper surface including anti-migration elements to contact said first vertebra when said implant is positioned within the interbody space, a lower surface including anti-migration elements to contact said second vertebra when said implant is positioned within the interbody space, a distal wall, a proximal wall, a first sidewall and a second sidewall, said distal wall, proximal wall, first sidewall, and second sidewall comprising a radiolucent material;

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.